Compare STRT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | IFRX |
|---|---|---|
| Founded | 1908 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.6M | 86.0M |
| IPO Year | 1995 | 2017 |
| Metric | STRT | IFRX |
|---|---|---|
| Price | $81.26 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 53.9K | ★ 909.6K |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.55 | N/A |
| EPS | ★ 5.73 | N/A |
| Revenue | ★ $578,413,000.00 | $73,729.00 |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $4.12 | $1,075.42 |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | ★ 6.83 | N/A |
| 52 Week Low | $31.57 | $0.71 |
| 52 Week High | $83.07 | $2.77 |
| Indicator | STRT | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 42.44 |
| Support Level | $77.08 | $1.00 |
| Resistance Level | $81.29 | $1.12 |
| Average True Range (ATR) | 3.71 | 0.09 |
| MACD | 0.54 | -0.01 |
| Stochastic Oscillator | 90.20 | 36.09 |
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.